Sumitomo Pharma’s Enzomenib Gains FDA Orphan Drug Status for ALL
MARLBOROUGH, Mass., July 30, 2026 Sumitomo Pharma America announced that the U.S. Food and Drug Administration (FDA) has granted...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MARLBOROUGH, Mass., July 30, 2026 Sumitomo Pharma America announced that the U.S. Food and Drug Administration (FDA) has granted...
MENLO PARK, Calif., June 30, 2026 Orca Bio announced that the U.S. Food and Drug Administration (FDA) has approved...
ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 Ascentage Pharma announced that 17 major clinical advances across its hematology...
